{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:36:42Z","timestamp":1779194202243,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.vhri.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T01:35:03Z","timestamp":1623461703000},"page":"142-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Annual Costs Incurred in Managing Adverse Drug Reactions Attributable to Fixed-Dose Combination Highly Active Antiretroviral Therapy in an Outpatient Antiretroviral Clinic in Gauteng: A Budget Impact Analysis"],"prefix":"10.1016","volume":"25","author":[{"given":"Grace","family":"Chikeya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frasia","family":"Oosthuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Bangalee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2021.04.004_bib1","author":"Hoffmann"},{"issue":"5","key":"10.1016\/j.vhri.2021.04.004_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064459","article-title":"Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study","volume":"8","author":"Velen","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vhri.2021.04.004_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2325957416686190","article-title":"Zidovudine- versus tenofovir-based antiretroviral therapy for the initial treatment of HIV infection in the ethnic minority region of Liangshan Prefecture, Sichuan Province, China","volume":"16","author":"Cheung","year":"2017","journal-title":"J\u00a0Int Assoc Provid AIDS Care"},{"issue":"11","key":"10.1016\/j.vhri.2021.04.004_bib7","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/tmi.12563","article-title":"Virological efficacy with first-line antiretroviral treatment in India: predictors of viral failure and evidence of viral resuppression","volume":"20","author":"Shet","year":"2015","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vhri.2021.04.004_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874613601711010001","article-title":"Clinical outcomes of tenofovir versus zidovudine-based regimens among people living with HIV\/AIDS: a two years retrospective cohort study","volume":"11","author":"Ayele","year":"2017","journal-title":"Open AIDS J"},{"key":"10.1016\/j.vhri.2021.04.004_bib9","article-title":"Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-na\u00efve individuals","volume":"10","author":"Spaulding","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.vhri.2021.04.004_bib10","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/tmi.12509","article-title":"Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?","volume":"20","author":"Labhardt","year":"2015","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vhri.2021.04.004_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.22159\/ajpcr.2017.v10s5.23107","article-title":"Comparison of zidovudine combination and tenofovir combination on the effectiveness of therapy and side effects in HIV\/AIDS patients in RSAL mintohardjo","volume":"10","author":"Insaniputri","year":"2017","journal-title":"Asian J Pharm Clin Res"},{"issue":"8","key":"10.1016\/j.vhri.2021.04.004_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042834","article-title":"Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring","volume":"7","author":"von Wyl","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vhri.2021.04.004_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAD.0b013e328340fdf8","article-title":"Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis","volume":"25","author":"Bendavid","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.vhri.2021.04.004_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8095609","article-title":"Evaluation of adverse drug reaction profile of drugs used as first-line antiretroviral therapy","volume":"2018","author":"Chowta","year":"2018","journal-title":"Interdiscip Perspect Infect Dis"},{"issue":"11","key":"10.1016\/j.vhri.2021.04.004_bib15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3855\/jidc.1908","article-title":"Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program","volume":"6","author":"Mudzviti","year":"2012","journal-title":"J\u00a0Infect Dev Ctries"},{"issue":"2","key":"10.1016\/j.vhri.2021.04.004_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10461-016-1545-0","article-title":"The role of ARV associated adverse drug reactions in influencing adherence among HIV-infected individuals: a systematic review and qualitative meta-synthesis","volume":"21","author":"Li","year":"2017","journal-title":"AIDS Behav"},{"key":"10.1016\/j.vhri.2021.04.004_bib17","first-page":"87","article-title":"Adverse drug reactions of highly active antiretroviral therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study","volume":"12","author":"Luma","year":"2012","journal-title":"Pan Afr Med J"},{"issue":"5","key":"10.1016\/j.vhri.2021.04.004_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/2325957414535978","article-title":"Adverse drug reactions to antiretroviral therapy in HIV-infected patients at the largest public hospital in Nicaragua","volume":"13","author":"Lor\u00edo","year":"2014","journal-title":"J\u00a0Int Assoc Provid AIDS Care"},{"issue":"14","key":"10.1016\/j.vhri.2021.04.004_bib19","first-page":"103","article-title":"Incidence of adverse drug reactions in patients on antiretroviral therapy: a study of pharmaceutical care in HIV interventions in a tertiary health facility in Southern Nigeria","volume":"6","author":"Agada","year":"2016","journal-title":"Res Hum Soc Sci"},{"key":"10.1016\/j.vhri.2021.04.004_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-12-7","article-title":"Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria","volume":"12","author":"Eluwa","year":"2012","journal-title":"BMC Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.vhri.2021.04.004_bib22","first-page":"2229","article-title":"Peventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig","year":"1992","journal-title":"Am J Hosp Pharm"},{"issue":"12","key":"10.1016\/j.vhri.2021.04.004_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189322","article-title":"Time to development of adverse drug reactions and associated factors among adult HIV positive patients on antiretroviral treatment in Bahir Dar City, Northwest Ethiopia","volume":"12","author":"Kindie","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vhri.2021.04.004_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4236\/pp.2015.63021","article-title":"A\u00a0time to event analysis of adverse drug reactions due to tenofovir, zidovudine and stavudine in a cohort of patients receiving antiretroviral treatment at an outpatient clinic in Zimbabwe","volume":"6","author":"Mudzviti","year":"2015","journal-title":"Pharmacol Pharm"},{"issue":"3","key":"10.1016\/j.vhri.2021.04.004_bib26","first-page":"243","article-title":"Adverse drug reactions associated with antiretroviral therapy in South Africa","volume":"15","author":"Birbal","year":"2016","journal-title":"Afr J AIDS Res"},{"issue":"4","key":"10.1016\/j.vhri.2021.04.004_bib27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40264-015-0277-9","article-title":"Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda","volume":"38","author":"Ndagije","year":"2015","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.vhri.2021.04.004_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/2229-3485.111784","article-title":"Adverse drug reactions to antiretroviral therapy: results from spontaneous reporting system in Nigeria","volume":"4","author":"Agu","year":"2013","journal-title":"Perspect Clin Res"},{"issue":"1","key":"10.1016\/j.vhri.2021.04.004_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40360-019-0307-9","article-title":"Nature and prevalence of adverse drug reaction of antiretroviral medications in Halibet National Referral Hospital: a retrospective study","volume":"20","author":"Hagos","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.vhri.2021.04.004_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12981-015-0044-0","article-title":"An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa","volume":"12","author":"Masenyetse","year":"2015","journal-title":"AIDS Res Ther"},{"issue":"2","key":"10.1016\/j.vhri.2021.04.004_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.302","article-title":"Impact of comorbidity on adverse drug reaction profile in a cohort of patients treated with Artemisinin combination therapies for uncomplicated malaria in Nigeria","volume":"5","author":"Bassi","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"10.1016\/j.vhri.2021.04.004_bib32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jval.2012.10.021","article-title":"Comparative incidence and healthcare costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy","volume":"16","author":"Johnston","year":"2013","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.vhri.2021.04.004_bib33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/hiv.12145","article-title":"Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors","volume":"15","author":"Simpson","year":"2014","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.vhri.2021.04.004_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/2325957415594883","article-title":"Economic burden of HIV antiretroviral therapy adverse events in the United States","volume":"15","author":"Dekoven","year":"2016","journal-title":"J\u00a0Int Assoc Provid AIDS Care"},{"issue":"1","key":"10.1016\/j.vhri.2021.04.004_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14302\/issn.2324-7339.jcrhap-12-71","article-title":"Evaluation of direct cost of adverse drug reactions to highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients","volume":"1","author":"Rajesh","year":"2012","journal-title":"J\u00a0Clin Res HIV AIDS Prev"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:13:54Z","timestamp":1761941634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109921000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"alternative-id":["S2212109921000546"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2021.04.004","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Annual Costs Incurred in Managing Adverse Drug Reactions Attributable to Fixed-Dose Combination Highly Active Antiretroviral Therapy in an Outpatient Antiretroviral Clinic in Gauteng: A Budget Impact Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}